The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.
Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.
A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.
Publications found:
8,499
Sort by:
Diphtheria R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Diphtheria Pipeline Overview The Q4 Diphtheria pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for D...
October 2020
92 pages
Genital Herpes R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Genital Herpes Pipeline Overview The Q4 Genital Herpes pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under developme...
October 2020
128 pages
Gonorrhea R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Gonorrhea Pipeline Overview The Q4 Gonorrhea pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Gon...
October 2020
94 pages
Grass Pollen Allergy R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Grass Pollen Allergy Pipeline Overview The Q4 Grass Pollen Allergy pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs under d...
October 2020
62 pages
Hepatitis A R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Hepatitis A Pipeline Overview The Q4 Hepatitis A pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for...
October 2020
57 pages
Hepatitis C (HCV) R&D Pipeline Analysis Report, Q4 2020
US$ 2,199.00
Hepatitis C (HCV) Pipeline Overview The Q4 Hepatitis C (HCV) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under dev...
October 2020
210 pages
Hepatitis D R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Hepatitis D Pipeline Overview The Q4 Hepatitis D pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for...
October 2020
62 pages
Hereditary Angioedema R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Hereditary Angioedema Pipeline Overview The Q4 Hereditary Angioedema pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs under...
October 2020
104 pages
Hyperglycemia R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Hyperglycemia Pipeline Overview The Q4 Hyperglycemia pipeline report is part of the VPA Metabolic Disorder disease pipeline service. This quarterly review describes the pipeline of drugs under develop...
October 2020
30 pages
Hyperinsulinemia R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Hyperinsulinemia Pipeline Overview The Q4 Hyperinsulinemia pipeline report is part of the VPA Metabolic Disorder disease pipeline service. This quarterly review describes the pipeline of drugs under d...
October 2020
63 pages
Hypoglycemia R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Hypoglycemia Pipeline Overview The Q4 Hypoglycemia pipeline report is part of the VPA Metabolic Disorder disease pipeline service. This quarterly review describes the pipeline of drugs under developme...
October 2020
81 pages
Impetigo R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Impetigo Pipeline Overview The Q4 Impetigo pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Impet...
October 2020
51 pages
Influenza B Infections R&D Pipeline Analysis Report, Q4 2020
US$ 2,199.00
Influenza B Infections Pipeline Overview The Q4 Influenza B Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs...
October 2020
162 pages
Insulin Resistance R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Insulin Resistance Pipeline Overview The Q4 Insulin Resistance pipeline report is part of the VPA Metabolic Disorder disease pipeline service. This quarterly review describes the pipeline of drugs und...
October 2020
53 pages
Japanese Encephalitis R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Japanese Encephalitis Pipeline Overview The Q4 Japanese Encephalitis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs u...
October 2020
51 pages
Kaposi Sarcoma R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Kaposi Sarcoma Pipeline Overview The Q4 Kaposi Sarcoma pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under developme...
October 2020
72 pages
Lassa Fever R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Lassa Fever Pipeline Overview The Q4 Lassa Fever pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for...
October 2020
65 pages
Lyme Disease R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Lyme Disease Pipeline Overview The Q4 Lyme Disease pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development f...
October 2020
68 pages
Measles R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Measles Pipeline Overview The Q4 Measles pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Measles...
October 2020
54 pages
Meningitis R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Meningitis Pipeline Overview The Q4 Meningitis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for M...
October 2020
64 pages
Mumps R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Mumps Pipeline Overview The Q4 Mumps pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Mumps, prov...
October 2020
40 pages
Myasthenia Gravis R&D Pipeline Analysis Report, Q4 2020
US$ 2,199.00
Myasthenia Gravis Pipeline Overview The Q4 Myasthenia Gravis pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs under develop...
October 2020
162 pages
